AU2008360937B9 - Methods of enhancing adjuvanticity of vaccine compositions - Google Patents

Methods of enhancing adjuvanticity of vaccine compositions Download PDF

Info

Publication number
AU2008360937B9
AU2008360937B9 AU2008360937A AU2008360937A AU2008360937B9 AU 2008360937 B9 AU2008360937 B9 AU 2008360937B9 AU 2008360937 A AU2008360937 A AU 2008360937A AU 2008360937 A AU2008360937 A AU 2008360937A AU 2008360937 B9 AU2008360937 B9 AU 2008360937B9
Authority
AU
Australia
Prior art keywords
cells
vaccine
pbs57
ova
pbs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008360937A
Other languages
English (en)
Other versions
AU2008360937A1 (en
AU2008360937A2 (en
AU2008360937B2 (en
Inventor
Vincent Serra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abivax SA
Original Assignee
Abivax SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abivax SA filed Critical Abivax SA
Publication of AU2008360937A1 publication Critical patent/AU2008360937A1/en
Publication of AU2008360937A2 publication Critical patent/AU2008360937A2/en
Assigned to WITTYCELL reassignment WITTYCELL Amend patent request/document other than specification (104) Assignors: WITTYCELL S.A.S.
Publication of AU2008360937B2 publication Critical patent/AU2008360937B2/en
Application granted granted Critical
Publication of AU2008360937B9 publication Critical patent/AU2008360937B9/en
Assigned to ABIVAX reassignment ABIVAX Request for Assignment Assignors: WITTYCELL
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU2008360937A 2007-08-29 2008-08-29 Methods of enhancing adjuvanticity of vaccine compositions Ceased AU2008360937B9 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96873107P 2007-08-29 2007-08-29
US60/968,731 2007-08-29
PCT/IB2008/003016 WO2010023498A1 (en) 2007-08-29 2008-08-29 Methods of enhancing adjuvanticity of vaccine compositions

Publications (4)

Publication Number Publication Date
AU2008360937A1 AU2008360937A1 (en) 2010-03-04
AU2008360937A2 AU2008360937A2 (en) 2010-04-29
AU2008360937B2 AU2008360937B2 (en) 2014-01-16
AU2008360937B9 true AU2008360937B9 (en) 2014-02-13

Family

ID=42061962

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008360937A Ceased AU2008360937B9 (en) 2007-08-29 2008-08-29 Methods of enhancing adjuvanticity of vaccine compositions

Country Status (14)

Country Link
US (1) US8916164B2 (https=)
EP (1) EP2190475B1 (https=)
JP (1) JP5539890B2 (https=)
KR (1) KR101540081B1 (https=)
CN (1) CN101820909A (https=)
AU (1) AU2008360937B9 (https=)
BR (1) BRPI0815846A2 (https=)
ES (1) ES2558157T3 (https=)
HR (1) HRP20151356T1 (https=)
PL (1) PL2190475T3 (https=)
PT (1) PT2190475E (https=)
RU (1) RU2491090C2 (https=)
WO (1) WO2010023498A1 (https=)
ZA (1) ZA201001477B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8207135B2 (en) 2007-12-05 2012-06-26 Wittycell Compositions for and methods of enhancing the immune response to antigens
ES2617510T3 (es) 2012-04-26 2017-06-19 Riken Nuevo carbamato de glicolípido y uso del mismo
CN117222414A (zh) 2021-03-01 2023-12-12 脱落性治疗公司 用于激活恒定自然杀伤t-细胞的化合物和用于消除炎性衰老细胞的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008005824A1 (en) * 2006-06-30 2008-01-10 The Scripps Research Institute Adjuvants and methods of use

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242800A (en) * 1990-01-30 1993-09-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Receptor for pathogenic fungi
US5936076A (en) * 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
TW261533B (https=) * 1992-07-16 1995-11-01 Kirin Brewery
EP0666268B1 (en) * 1992-10-22 2000-04-19 Kirin Beer Kabushiki Kaisha Novel sphingoglycolipid and use thereof
EP0694558B1 (en) * 1993-04-15 1999-01-27 Kirin Beer Kabushiki Kaisha Novel sphingoglycolipid and use thereof
RO117533B1 (ro) * 1993-05-14 2002-04-30 Cytel Corp San Diego DERIVATI DE ANALOGI SIALIL LeX INHIBITORI AI ADEZIUNII CELULARE SI COMPOZITIE FARMACEUTICA CU ACESTIA
US6054433A (en) * 1994-11-03 2000-04-25 The Regents Of The University Of California Methods and compositions for stimulating tissue growth and epithelial moisturization
US5785975A (en) * 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
EP0821068A3 (en) * 1996-03-29 1999-06-02 Rohm And Haas Company Novel sphingolipids and a process thereto
US6417167B1 (en) * 1997-02-05 2002-07-09 Kirin Beer Kabushiki Kaisha Lyophilized compositions containing shingoglycolipid and process for preparing them
CN1121223C (zh) 1997-02-05 2003-09-17 麒麟麦酒株式会社 含有神经鞘糖脂的冷冻干燥组合物及其制造方法
ATE286735T1 (de) 1997-04-10 2005-01-15 Kirin Brewery Verwendung von a-glycosylceramiden zur herstellung eines therapeutischen mittelszur behandlung von autoimmunkrankheiten
JP2001527046A (ja) 1997-12-30 2001-12-25 エイプラス サイエンス インベスト アーベー ガラクトシルセラミド、グルコシルセラミド、ラクトシルセラミド、並びに前糖尿病、糖尿病および／または関連合併症の予防もしくは治療に使用するためのその特定キャッチャー
EP1053243B1 (en) * 1998-02-12 2011-03-30 Emory University Sphingolipid derivatives and their methods of use
SE9900496D0 (sv) * 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine formulation
JP2003511421A (ja) * 1999-10-12 2003-03-25 ナショナル リサーチ カウンシル オブ カナダ 細胞毒性ｔリンパ球（ｃｔｌ）応答を誘発し、そして細胞内病原体及び癌に対してワクチン接種された宿主を保護するための無細胞ワクチンのための免疫調節キャリヤーとしてのアルキオソーム
US20030157113A1 (en) 1999-12-28 2003-08-21 Terman David S. Compositions and methods for treatment of neoplastic disease
AU2001252599A1 (en) * 2000-04-28 2001-11-12 Orient Cancer Therapy Co., Ltd. Remedies for cancer
JP4410913B2 (ja) * 2000-06-12 2010-02-10 壽製薬株式会社 新規糖脂質誘導体の製造方法
WO2001098317A2 (en) * 2000-06-22 2001-12-27 The Brigham And Women's Hospital, Inc. Alpha-glycosylceramides for treating bacterial and fungal infections
WO2002018539A2 (en) * 2000-08-25 2002-03-07 Lysometrix Corporation Method for assaying the activity of lysosomal enzymes
CN1561389A (zh) 2001-07-25 2005-01-05 纽约大学 糖基神经酰胺作为用于抗传染病和癌症的疫苗的佐剂的用途
KR100549866B1 (ko) 2001-08-22 2006-02-08 고려대학교 산학협력단 암치료 및 예방 제제
RU2360699C2 (ru) * 2001-10-03 2009-07-10 Новартис Вэксинес Энд Дайэгностикс Инк. Композиции менингококковых вакцин с адъювантами
CN1578667A (zh) * 2001-11-06 2005-02-09 东方癌症治疗株式会社 抗癌组合物
US7273853B2 (en) * 2002-05-13 2007-09-25 Enanta Pharmaceuticals, Inc. 6-11 bicyclic ketolide derivatives
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
WO2003105769A2 (en) 2002-06-13 2003-12-24 New York University Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
US7645873B2 (en) * 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
WO2004094444A1 (en) 2003-03-20 2004-11-04 Brigham Young University 6'-amino-6'-deoxygalactosylceramides
TWI329130B (en) * 2003-06-19 2010-08-21 Bestewil Holding Bv Functionally reconstituted viral membranes containing adjuvant
GB0314682D0 (en) 2003-06-24 2003-07-30 Isis Innovation Materials and methods relating to the modulation of T cell response to soluble antigen
US7771726B2 (en) * 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
CN1964626A (zh) 2004-03-31 2007-05-16 纽约大学 新型合成c－糖脂、其合成及其治疗传染病、癌症和自身免疫性疾病的用途
CA2577009C (en) 2004-08-27 2017-05-02 Albert Einstein College Of Medicine, Inc. Ceramide derivatives as modulators of immunity and autoimmunity
JP5005541B2 (ja) * 2004-09-03 2012-08-22 ザ ユニヴァーシティー オヴ シカゴ Ｎｋｔ細胞の活性化方法
JP5090928B2 (ja) * 2004-12-28 2012-12-05 ザ ロックフェラー ユニバーシティ Ｎｋｔ細胞に対する抗原としての糖脂質及びその類似体
CA2593715C (en) 2005-01-28 2015-05-05 Brigham Young University Bacterial glycolipid activation of cd1d-restricted nkt cells
KR100764678B1 (ko) 2005-07-13 2007-10-09 재단법인서울대학교산학협력재단 알파-갈락토실세라마이드를 아쥬반트로 포함하는 비강투여용 백신 조성물
EP1945651B1 (en) 2005-10-25 2014-06-25 The Ludwig Institute for Cancer Research Analogs of alpha galactosylceramide and uses thereof
PL2056842T3 (pl) * 2006-04-07 2013-03-29 Scripps Research Inst Modyfikowany galaktozyloceramid do leczenia chorób nowotworowych
CN101426523B (zh) 2006-04-27 2013-03-27 财团法人首尔大学校产学协力财团 基于负载了天然杀伤t细胞的配体、和抗原的b细胞的疫苗
EP1938836A1 (en) 2006-12-28 2008-07-02 Universite Rene Descartes (Paris V) Compositions comprising a B subunit of shiga toxin and a means stimulating NKT cells
KR100868959B1 (ko) 2006-12-30 2008-11-17 재단법인서울대학교산학협력재단 알파-갈락토실세라마이드 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는면역보조용 약학적 조성물
EP2058011A1 (en) 2007-11-07 2009-05-13 Wittycell Nkt cell activating gycolipids covalently bound antigens and/or drug
US8207135B2 (en) * 2007-12-05 2012-06-26 Wittycell Compositions for and methods of enhancing the immune response to antigens
JP5809560B2 (ja) 2008-10-08 2015-11-11 アビヴァックス インフルエンザに対して使用するためのワクチン組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008005824A1 (en) * 2006-06-30 2008-01-10 The Scripps Research Institute Adjuvants and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIU, Y., et al., "A modified alpha-galactosyl ceramide for staining and stimulating natural killer T cells," Journal of Immunological Methods, 2006, Vol. 312, No. 1-2, pages 34-39. *

Also Published As

Publication number Publication date
KR101540081B1 (ko) 2015-07-29
PL2190475T3 (pl) 2016-04-29
KR20100072211A (ko) 2010-06-30
EP2190475A1 (en) 2010-06-02
CN101820909A (zh) 2010-09-01
RU2491090C2 (ru) 2013-08-27
RU2010111766A (ru) 2011-10-10
JP5539890B2 (ja) 2014-07-02
US8916164B2 (en) 2014-12-23
PT2190475E (pt) 2016-02-11
ES2558157T3 (es) 2016-02-02
AU2008360937A1 (en) 2010-03-04
AU2008360937A2 (en) 2010-04-29
EP2190475B1 (en) 2015-10-28
ZA201001477B (en) 2010-12-29
AU2008360937B2 (en) 2014-01-16
BRPI0815846A2 (pt) 2017-05-30
WO2010023498A1 (en) 2010-03-04
HRP20151356T1 (hr) 2016-01-01
JP2011518760A (ja) 2011-06-30
US20100285042A1 (en) 2010-11-11
WO2010023498A8 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
EP2231145B1 (en) Use of glycosylceramides for enhancing the immune response to antigens
AU2007269299A2 (en) Adjuvants and methods of use
DK2231196T3 (en) Increase in the immune response by peptide-antigen binding
AU2008360937B9 (en) Methods of enhancing adjuvanticity of vaccine compositions
DK2190475T3 (en) PROCEDURES FOR IMPROVING ADJUSTABILITY IN VACCINE COMPOSITIONS
Nitcheu et al. as Vaccine Adjuvants

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 12 APR 2010

SREP Specification republished
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ABIVAX

Free format text: FORMER OWNER WAS: WITTYCELL

MK14 Patent ceased section 143(a) (annual fees not paid) or expired